GeoVax Labs Files Q3 2024 10-Q, Details ATM Program & BARDA Contract
Ticker: GOVX · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 832489
Sentiment: neutral
Topics: 10-Q, financing, government-contract, biotech
TL;DR
GeoVax Q3 2024 10-Q is in: ATM program active, BARDA contract details out. Check financials.
AI Summary
GeoVax Labs, Inc. filed its Q3 2024 10-Q report on November 12, 2024, covering the period ending September 30, 2024. The company is involved in the pharmaceutical preparations industry. Key events include subsequent events related to an At-the-Market (ATM) program in October 2024 and a BARDA contract. Financial details and operational updates for the third quarter are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational updates for GeoVax Labs, including details on recent financing activities and government contracts.
Risk Assessment
Risk Level: medium — The company operates in the volatile pharmaceutical sector, and the filing likely contains details on ongoing clinical trials, regulatory hurdles, and financial performance that could impact its stock.
Key Numbers
- Q3 2024 — Reporting Period (Covers the third quarter of 2024)
- September 30, 2024 — Period End Date (The end date for the financial data presented)
- November 12, 2024 — Filing Date (Date the 10-Q was officially submitted to the SEC)
Key Players & Entities
- GeoVax Labs, Inc. (company) — Filer of the 10-Q report
- 20240930 (date) — End of the reporting period
- 20241112 (date) — Filing date of the 10-Q
- PHARMACEUTICAL PREPARATIONS [2834] (industry) — Standard Industrial Classification
- BARDA (company) — Mentioned in relation to a contract
FAQ
What were the key financial results for GeoVax Labs in Q3 2024?
The filing covers the period ending September 30, 2024, and details financial performance, though specific dollar amounts for revenue or net income are not explicitly listed in the provided header information.
What is the 'At-the-Market Program' mentioned in the filing?
The filing indicates subsequent events related to an 'At-the-Market Program' (govx:AttheMarketProgramMember) occurring in October 2024, suggesting the company may have sold shares during this period.
What is the significance of the BARDA contract?
The filing references a 'BARDA Contract' (govx:BARDAContractMember) and 'Grant' (us-gaap:GrantMember) for the periods of January 1, 2024 - September 30, 2024, and July 1, 2024 - September 30, 2024, indicating a relationship with the Biomedical Advanced Research and Development Authority.
When was GeoVax Labs incorporated or previously known by other names?
GeoVax Labs, Inc. was formerly known as DAUPHIN TECHNOLOGY INC (name change 19940826) and SUCCESSO INC (name change 19910410), and its state of incorporation is Delaware.
What is GeoVax Labs' primary business sector?
GeoVax Labs, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,451 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-11-12 16:01:45
Key Financial Figures
- $0.001 — ange on which Registered Common Stock $0.001 par value GOVX The Nasdaq Capital M
Filing Documents
- govx20240930_10q.htm (10-Q) — 679KB
- ex_744201.htm (EX-31.1) — 14KB
- ex_744202.htm (EX-31.2) — 14KB
- ex_744203.htm (EX-32.1) — 6KB
- ex_744204.htm (EX-32.2) — 7KB
- 0001437749-24-034530.txt ( ) — 3193KB
- govx-20240930.xsd (EX-101.SCH) — 34KB
- govx-20240930_def.xml (EX-101.DEF) — 223KB
- govx-20240930_lab.xml (EX-101.LAB) — 196KB
- govx-20240930_pre.xml (EX-101.PRE) — 242KB
- govx-20240930_cal.xml (EX-101.CAL) — 26KB
- govx20240930_10q_htm.xml (XML) — 311KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION Item 1 Condensed Consolidated Financial Statements: Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three-month and nine-month periods ended September 30, 2024 and 2023 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three-month and nine-month periods ended September 30, 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2024 and 2023 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 10 Item 3
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 16 Item 4
Controls and Procedures
Controls and Procedures 16
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 17 Item 1A
Risk Factors
Risk Factors 17 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 17 Item 3 Defaults Upon Senior Securities 17 Item 4 Mine Safety Disclosures 17 Item 5 Other Information 17 Item 6 Exhibits 18
-- FINANCIAL INFORMATION
Part I -- FINANCIAL INFORMATION Item 1
Financial Statements
Financial Statements GEOVAX LABS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2024 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 8,592,523 $ 6,452,589 Accounts receivable 547,574 - Prepaid expenses 1,729,326 1,433,153 Total current assets 10,869,423 7,885,742 Property and equipment, net 171,615 209,689 Other assets 71,010 1,187,788 Total assets $ 11,112,048 $ 9,283,219 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,147,952 $ 2,802,950 Accrued expenses 460,220 716,931 Total current liabilities 2,608,172 3,519,881 Commitments (Note 5) Stockholders' equity: Common stock, $ .001 par value: Authorized shares – 150,000,000 and 600,000,000 at September 30, 2024 and December 31, 2023, respectively Issued and outstanding shares – 8,609,308 and 1,977,152 at September 30, 2024 and December 31, 2023, respectively 8,609 1,977 Additional paid-in capital 129,588,694 110,125,146 Accumulated deficit ( 121,093,427 ) ( 104,363,785 ) Total stockholders' equity 8,503,876 5,763,338 Total liabilities and stockholders' equity $ 11,112,048 $ 9,283,219 See accompanying notes to condensed consolidated financial statements. 1 GEOVAX LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue from government contract $ 2,789,484 $ - $ 3,090,161 $ - Operating expenses: Research and development 7,402,884 6,947,979 16,105,480 14,486,896 General and administrative 1,241,176 1,651,775 3,784,559 4,562,293 Total operating expenses 8,644,060 8,599,754 19,890,039 19,049,189 Loss from operations ( 5,854,576 ) ( 8,599,754 ) ( 16,799,878 ) ( 19,049,189 ) Other income (expense): Interest income 53,191 190,936 91,611 674,835 Interest expense ( 14,0